申请人:BAYER SCHERING PHARMA AG
公开号:WO2010124826A1
公开(公告)日:2010-11-04
The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer.
本发明涉及一种通式(I)的替代咪唑喹喔啉化合物,作为Mps-1激酶或TTK的抑制剂,并对炎症和癌症具有活性。